Figure 2.

Zalcitabine-induced TFAM degradation promotes ferroptosis. (A-C) Western blot analysis of TFAM expression in the indicated human PDAC cells following treatment with zalcitabine (20 µM) in the absence or presence of bortezomib (500 nM) or TMP (10 µM) or epoxymicin (500 nM) for 72 h. (D-I) The indicated human PDAC cells were treated with zalcitabine (20 µM) in the absence or presence of TMP (5 or 10 µM) for 72 h. The relative levels of mtDNA copy number (D), oxygen consumption (E), ATP production (F), total ROS (G), MDA production (H), and cell death (I) were assayed using commercially available assay kits (n = 3, *P < 0.05 versus zalcitabine-alone group)